Emyria (ASX:EMD) says it is "well positioned" to accelerate patient access to psychedelic substances following the TGA's decision to reclassify psilocybin and MDMA from 1 July this year.
Emyria to expand MDMA programs following TGA psychedelic decision
February 6, 2023 Australian Biotech
Latest Video
New Stories
-
Australian medtech secures funds to advance real-time breast cancer surgery technology
February 13, 2026 - - Australian Biotech -
The Dispatched Podcast 'Week in Review' - 13 February
February 13, 2026 - - Podcast -
PBAC to reconsider broader vaccine funding after late addition to March agenda
February 13, 2026 - - Latest News -
Ten years of process 'improvements' is almost the point, says Anne Ruston
February 13, 2026 - - Latest News -
Senate scrutiny of PBS rules after Canberra family highlights lack of biologic access
February 12, 2026 - - Latest News -
There is no negotiation, yet, so be careful not to give the impression of conceding anything
February 11, 2026 - - Latest News -
Arrotex and Pfizer forge strategic pharmacy partnership for ENBREL in Australia
February 11, 2026 - - Latest News

